Low risk of hepatitits B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

Liver Transplantation

Volumn 13, Issue 3, 2007, Pages 374-381

  Wong, Stephen N ^a   Chu, Chi Jen ^a   Wai, Chun Tao ^a   Howell, Terese ^a,b   Moore, Charles ^b   Fontana, Robert J ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PREDNISONE; TACROLIMUS; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; RECURRENCE RISK; RECURRENT INFECTION; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; AGED; BLOOD; CLINICAL TRIAL; GENETICS; HEPATITIS B VIRUS; LONGITUDINAL STUDY; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33947414107     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21041     Document Type: Article

References (45)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ. Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626.
2. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104-111.
3. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005:11: 716-732.
4. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin Hepatology 1996;24:1327-1333.
5. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
6. Han SH, Ofman J, Holt C, King K, Kunder G. Chen P. et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
7. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001:33:424-432.
8. Mutimer D, Dushelko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
9. Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000;69:1403-1407.
10. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003;3:999-1002.
11. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
12. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998: 28:585-589.
13. Marzano A, Sallzzoni M, Debernardi-Venon W, Smedile A, Franchello A. Ciancio A. et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
14. Dan YY, Wal CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006;12:736-746.
15. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000;32: 1189-1195.
16. Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, Carrera Alonso E, Garcia Gonzalez M. et al. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary result. Transplant Proc 2003;35: 1848-1849.
17. Karasu Z, Ozacar T, Akarca U, Ersoz G, Erensoy S, Gunsar F, et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005;12:212-215.
18. Starkel P, Stoffel M, Lerut J, Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005;11:1228-1234.
19. Gunther M, Neuhaus R, Bauer T, Jilg W, Holtz JA. Bienzle U. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl 2006;12:316-319.
20. Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E, Mateo Lindeman M. Garcia Gonzalez M, de Vicente Lopez E, et al. Use of combined treatment of hepatitis B immune globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. Transplant Proc 2003:35: 1844-1845.
21. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004;36:535-538.
22. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006;12:253-258.
23. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C. et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003:9;182-187.
24. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.
25. Karademir S, Astarcioglu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, et al. Prophylactic use of low-dose. on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006;38:579-583.
26. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J. Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000;6:434-439.
27. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-894.
28. Butl M. Mas A. Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-lerm lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-817.
29. Buti M, Mas A, Prieto M. Casafont F, Gonzalez A, Miras M, et al. Five year follow-up of a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation [abstract]. Hepatology 2005;42(Suppl):491A.
30. Roche B, Feray C. Gigou M, Roque-Afonso AM, Arulnaden JL. Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86-95.
31. Chu CJ, Fontana RJ, Moore C, Wai CT, Punch J, Su G, Lok AS. Efficacy of HBIG weaning in the long-term prophylaxis of HBV reinfection following liver transplantation [abstract]. Hepatology 2002;36(Suppl):221A.
32. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C. Andreone P, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006;44:1094-1097.
33. Park SJ, Palk SW, Choi MS, Lee JH, Koh KC, Kim SJ, et al. Is lamivudine with 1-week HBIG as effective as long-term high-dose HBIg in HBV prophylaxis after liver transplantation? Transplant Proc 2002;34:1252-1254.
34. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. Prolonged follow-up of HBV liver transplanted patient: results from a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation (abstract). Journal of Hepatology 2003;38:37
35. Wang RT. Kim D, Yao FY, Roberts JP, Terrault NA. Long-term-efficacy of different regimens of combination hepatitis B immunoglobulin (HBIG) and antivirals in preventing hepatitis B virus (HBV) recurrence post-transplantation (LT) [abstract]. Hepatology 2005;42:491A.
36. Mutimer D, Pillay D, Dragon E. Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infectlon after liver transplantation. J Hepatol 1999;30:715-721.
37. Noborg U, Gusdal A. Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000;32: 249-252.
38. Zoulim F. Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation? J Hepatol 2003;38:850-852.
39. Ireland JH, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GK, et al. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000;31:1176-1182.
40. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003;77:11833-11841.
41. Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, et al. Long-term follow up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J Viral Hepat 2005;12:154-159.
42. Bock CT, Tulmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-273.
43. Chan HL, Chui, AK, Lau WY, Chan FK, Hui AY, Rao AR, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004;18:295-300.
44. Wai CT, Prabhakaran K, Wee A, Lee YM, Dan YY. Sutedja DS, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant Proc 2004;36;2313-2314.
45. Mutimer D, Pillay D, Shields P. Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46 107-113.